Surgery Partners spent just under $250 million to acquire ASCs last year, and is planning for more in 2023.
“Our team is currently managing a robust pipeline of potential targets in excess of $250 million,” said Wayne DeVeydt, executive chair of Surgery Partners in a March 1 earnings call transcribed by Seeking Alpha, later adding the company expects to generate more than $140 million in free cash flow this year and aims to increase free cash flow to $200 million by 2025.
The company started 2023 with $820 million in liquidity and has an eye on long-term growth, according to Becker’s.
“We have high confidence in the long-term growth prospects of Surgery Partners,” said Mr. DeVeydt. “The management team continues to demonstrate their ability to successfully navigate the challenges of our current macroeconomic environment, as it executes on organic and inorganic growth strategies to provide significant year-over-year growth.”
